Takeda completes sale of tachosil® to corza health

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that it has completed the previously announced sale of tachosil® fibrin sealant patch (“tachosil®”) to corza health, inc. (“corza”) for €350 million. tachosil® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. under the terms of the transaction, corza has acquired the assets and licenses that support the development
TAK Ratings Summary
TAK Quant Ranking